PDF(Pubmed)
Abstract：
UNASSIGNED: Dabigatran belongs to the new generation of direct oral anticoagulants (DOACs). Its advantages are oral administration and no need for international normalized ratio (INR) monitoring. Although its use has increased, its potential side effects on bone healing and remodeling have not been fully investigated. The present study aimed to evaluate the possible effects of dabigatran on early bone healing.
UNASSIGNED: Sixteen male Wistar rats were divided into two groups; in group A, 20-mg/kg dabigatran dose was administered orally daily for 15 days, while group B served as a control. Two circular bone defects (d=6 mm) were created on either side of the parietal bones. Two weeks after surgery and euthanasia of the animals, tissue samples (parietal bones that contained the defects) were harvested for histological and histomorphometric analysis. Statistical analysis was performed with a significance level of α=0.5.
UNASSIGNED: No statistically significant differences were found between the two groups regarding the regenerated bone (21.9% vs. 16.3%, P=0.172) or the percentage of bone bridging (63.3% vs. 53.5%, P=0.401).
UNASSIGNED: Dabigatran did not affect bone regeneration, suggesting that it might be a safer drug compared to older anticoagulants known to lead to bone healing delay.
UNASSIGNED: Sixteen male Wistar rats were divided into two groups; in group A, 20-mg/kg dabigatran dose was administered orally daily for 15 days, while group B served as a control. Two circular bone defects (d=6 mm) were created on either side of the parietal bones. Two weeks after surgery and euthanasia of the animals, tissue samples (parietal bones that contained the defects) were harvested for histological and histomorphometric analysis. Statistical analysis was performed with a significance level of α=0.5.
UNASSIGNED: No statistically significant differences were found between the two groups regarding the regenerated bone (21.9% vs. 16.3%, P=0.172) or the percentage of bone bridging (63.3% vs. 53.5%, P=0.401).
UNASSIGNED: Dabigatran did not affect bone regeneration, suggesting that it might be a safer drug compared to older anticoagulants known to lead to bone healing delay.
摘要：
■达比加群属于新一代直接口服抗凝剂（DOACs）。它的优点是口服给药，不需要国际标准化比率（INR）监测。虽然它的使用有所增加，其对骨愈合和骨重塑的潜在副作用尚未得到充分研究。本研究旨在评估达比加群对早期骨愈合的可能影响。
■16只雄性Wistar大鼠分为两组,每天口服20-mg/kg达比加群剂量，持续15天，B组作为对照。在顶骨的两侧产生两个圆形骨缺损(d=6mm)。手术和动物安乐死两周后，收集组织样本(包含缺损的顶骨)用于组织学和组织形态计量学分析。进行统计学分析,显著性水平为α=0.5。
■两组在再生骨方面无统计学差异（21.9%vs.16.3%,P=0.172）或骨桥接的百分比（63.3％vs.53.5%,P=0.401）。
■达比加群不影响骨骼再生，这表明，与已知会导致骨愈合延迟的旧抗凝剂相比，它可能是一种更安全的药物。
■16只雄性Wistar大鼠分为两组,每天口服20-mg/kg达比加群剂量，持续15天，B组作为对照。在顶骨的两侧产生两个圆形骨缺损(d=6mm)。手术和动物安乐死两周后，收集组织样本(包含缺损的顶骨)用于组织学和组织形态计量学分析。进行统计学分析,显著性水平为α=0.5。
■两组在再生骨方面无统计学差异（21.9%vs.16.3%,P=0.172）或骨桥接的百分比（63.3％vs.53.5%,P=0.401）。
■达比加群不影响骨骼再生，这表明，与已知会导致骨愈合延迟的旧抗凝剂相比，它可能是一种更安全的药物。
